Braveheart Bio, Inc.NASDAQ: BRVE

Braveheart Bio to Participate in Stifel Cardiometabolic Forum

· Issued by Braveheart Bio, Inc. via GlobeNewswire

Summary by 6ix AI

Braveheart Bio, Inc., a clinical-stage drug developer working on treatments for hypertrophic cardiomyopathy (a thickening of the heart muscle) and other serious heart diseases, will take part in the Stifel Virtual Cardiometabolic Forum. Management will join a fireside chat on Wednesday, September 30, 2026, at 12:30 p.m. EDT.

Key details

  • A live webcast will be available in the News & Events section of the Braveheart website, with a replay kept in a temporary archive after the event.

6ix AI wrote this summary from the release below and checked it against the release.

SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Stifel Virtual Cardiometabolic Forum, being held September 30. Management will participate in a fireside chat on Wednesday, September 30, 2026, at 12:30 p.m. EDT.

Interested parties may access a live webcast by visiting the News & Events section of the Braveheart website at https://ir.braveheart.bio/, with a replay available in a temporary archive following the event.

About Braveheart Bio

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio's lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring. For more information, please visit www.braveheart.bio.

Investor Relations Contact
Alexander Sharif
New Street Investor Relations
[email protected]

Media Contact
FGS Global
[email protected]

Braveheart Bio, Inc. on 6ix

Story so far

Earlier from Braveheart Bio

Later from Braveheart Bio

All Braveheart Bio news releases